Profil is the world’s leading CRO in metabolic research. As a full-service provider, we conduct early phase clinical trials within the indications of obesity, (pre)diabetes, and diabetes complications. We offer an unrivalled combination of science and professional conduct. This unique combination allows us to design and carry out best-in-class clinical trials for our clients.

Our in-house scientific expertise covers, among others, obesity and (pre-)diabetes, cardiometabolic research, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) as well as metabolic monitoring and medical technology. One of our core technologies is the hyperinsulinemic euglycemic clamp, used to address action profiles of insulin and insulin analogues, beta cell function and insulin sensitivity. To address human metabolic pathways glucose clamp studies are combined with isotope dilution techniques and tissue biopsies or with sophisticated imaging techniques in particular in NAFLD-/NASH-studies.

To be able to offer the best services for any glucose clamping setup, we have developed ClampArt, the next generation of glucose clamping. By owning a continuously updated database with entries of more than 30.000 well characterized individuals (healthy, healthy at-risk, type 1 and type 2 diabetes), we can recruit even the most complex clinical trials. We have a fully GMP certified pharmacy and in-house clinics with 80 beds and hold expertise in Data Management & Statistics and Regulatory Affairs.

In komIT, Profil together with the DDZ will be responsible for the preparation, conduct, and analysis of a proof-of concept study investigating potential beta-cell protective effects of an allosteric modulator of the GABA receptor developed by Algiax Pharmaceuticals.